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Incidence and Treatment of Rejection Episodes in Primary Orthotopic 
Liver Transplantation Under FK 506 
A.B. Jain, J.J. Fung, S. Todo, M. Alessiani, S. Takaya, K. Abu-Elmagd. A. Tzakis, and T.E. Starzl 
FOLLOWING the demonstration of the potent immu-
nosuppressive effect of FK 506 on human T lympho-
cyte activation fK~ and the prolongation of graft survival on 
experimental models.3-6 FK 506 has been applied success-
fully in clinical settings. 7• IO In this report. we present our 
experience with 1 ~ primary Ii .. er transplant patients 
treated with FK 506 as a primary immunosuppressive 
agent. 
This analysis focuses on the incidence of rejection. 
management of rejection episodes. and the role of concom-
itant use of prophylactic steroid in FK 506 treated patients. 
MATERIALS AND METHODS 
This study, which ~ as done at the L' niverSlI} of Pittsburgh. 
included patients ~ho underwent pnmary liver transplantation 
between August 18. 1989. and February 16. 1990. A prospective 
randomized trial of cyclosporine (eyA) and FK 506 was initiated 
afterwards. The 110 adul!s were between 18 and 69 years of age 
and the 15 children were between 4 months and 17 years of age. 
Seven children were s I year of age. Pnmary causes of hepatic 
failure are summarized in Table I. All the patients were followed 
up for ISO to 355 days cmean durauon ~·C days). There were 10 
deaths in the follow-up period. Eleven patJents required a second 
transplant and four patients required a third transplant. Subse· 
quent episodes of rejection in retransplants were not included for 
analysis. All patients received one dose of FK 506 cO.15 mg/kg/dl 
IV on the first day and 0.075 mg.'kg tWice a da~ as a constant 
infusion over 2 to 4 hours. Oml doses were introduced as soon as 
patients could tolerate oral t\uid s Yo ith a \anable penod of overlap 
with IV FK 506. II Subsequent adjustments 10 FK 506 dosage were 
made depending on hepatic graft function. adve~ effects from 
the drug. and the drug's plasma trough le\ el.,. The first 63 patients 
received I-g doses of prophylactic meth} Iprednisone after perfu-
sion of liver and then ~ll mg In four di, IJed do~s on the first 
postoperative day and then reduced by 40 mg e\'eryday until 20 
mg/d of maintenance was reached. cDoses .... ere scaled down for 
infants and children. ~fost children belo... the age of 8 years 
received half Ihe adult doses.) The remaining 62 patients received 
only 20 mg/d (10 mg/d children) of melh~lprednisone as prophy-
laxis. Steroids were reduced postoperatlyDel~ on an individualized 
basis. 
The clinical diagnosis of rejeclion was made by n~s in serum 
bilirubin and hepatic enz) mes in the absence of bihary complica-
Table 1. Indications of Primary liver Transplant (n = 125) 
Nonalcoholic cirrhosis 
Alcoholic Cirrhosis 
Cholestatic disease 
Biliary atresia 
Fulminant failure 
Tumor 
Miscellaneous 
45(36%) 
28 (22%) 
29(22%) 
8(7%) 
4 (3%) 
4(3%) 
8 (7%) 
lions. ior,.;hemic damage. or development of hepatitis I hepatitis B. 
non-A. non-B. or c~1Mmegalovirus [CMV)). In addition. the adult 
patients had protocol biopsies at 10 to 14 days posttransplantation 
and subsequently If clinically indicated. 
RESULTS 
In this group of 1:!5 patients. 115 (92.0'k) are well at the 
present time. One hundred nine patients (87.:!S'i) have their 
original grafts (Fig I). Three patients are alive with second 
transplants and the other three with third transplants. 
Rejecllon episodes were considered to be early when 
they occurred within 90 days and late when they occurred 
after 90 days (Tat-Ie 2). Forty-five patients (36'7c1 experi-
enced one episode of rejection. 6 patients (4.8'7c) two 
episodes. and I patient (0.8%) experienced three episodes 
of rejection v. ithin the first 90 days. whereas 73 patients 
(58.4%) remained free from any episode of rejection and 
did not require additional immunosuppression in the first 3 
months. Only 11 patients of 113 (9.7%) patients who were 
alive with primary grafts at 90 days experienced one 
episode of rejectiL'\fl and one patient (O.9'k-1 experienced 
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Fig 1. Percentage SlJrVlVal of patients and primary transplants on 
FK 506 over the foltow~p period (n = 125). 
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Table 2. Frequency of ReJKtlon 
Eat1Y within 90 days In : 125) 
1 
2 
3 
AejeC1ion free' 
Late rejectiOn after 9C days 
(n = 113) 
1 
2 
Rejection free' 
No. 01 
Patients 
45 
6 
1 
73 
11 
1 
101 
'Cumulahve rlllecliOn 7ee 66 pal1enls (52.8"JI.). 
Percentage 
36.0 
4.8 
0.8 
58.4 
9.7 
0.9 
89.4 
two episodes of rejection. Sixty-six patients EROKU~F had 
no rejection throughout the entire follow-up period. 
In 110 adult patients. the results were compared be-
tween the 54 who received initial high prophylactic doses 
of methylprednisone (group I. Table 3) and the 56 patients 
who received low doses of methyl prednisone (group 2. 
Table 3). 
In group I patients. 17 of the 54 (31 %) patients experi-
enced a first episode of rejection at mean of 18.3 (:!: 10.3 
So) days after transplantation. In group 2. '2.7 of 56 (48%) 
patients experienced a first episode of rejection at a mean 
time of 13.9 (:!: 10.7 SD) days. The apparent differences in 
episodes of rejection or timing of rejection were not 
statistically significant by chi·square t test analysis. The 
children were excluded from the foregoing analysis be-
cause they were not systematically biopsied. 
Treatment of rejection was catalogued for all recipients. 
adults as well as children. There were a total of73 episodes 
of rejection (early. late. recurrent). The majority of the 
rejection episodes were mild and were easily controlled 
with a single dose of I g IV methylprednisone ('2.8 episodes. 
38.4%) or a single dose of I g IV hydrocortisone (17 
episodes. 23.311il (Table 4). Thirteen E1TKU~F episodes of 
rejection required further bolus steroid therapy to control 
the rejection. Short courses of OKT3 (3 to 5 days. 5-10 
mL) were used to treat 15 episodes of rejection in 14 
patients. In six patients. this therapy was used as primary 
treatment to control rejection while in the other 7 patients. 
it was used in conjunction with additionaJ steroids. One 
patient was given two courses of OKT3. All the episodes 
of rejection were reversed completely except in two pa-
tients who required retransplantation due to persistent 
Table 3. Frequency of Rejection During the Arst 90 Days 
(Adults Only) 
High dose 01 prophyIactJe 
steroid (group 1) 
low dose 01 prophylactic 
steroid (group 2) 
EpisodeS.'Palienl 
("4) 
17154 (31) 
27156 (48) 
P:NS 
Dayoner-t 
(mean ~ SO) 
18.3 !: 10.3 
13.9!: 10.7 
P:NS 
Table 4. Treatment of Re)ec:tion 
Drug 
Hydrocortisone (1 g) 
Methylprednisone (1 g) 
OKT3 (3-5 d. 5-10 ml) 
929 
Episode (%) 
28 (38.2) 
17 (23.3) 
15 (20.5) 
rejection. OKD treatment was not considered in these 
two patients since the first patient was in the early part of 
the trial and the second patient had a primary nonfunction 
and received a second transplant 2 days later when a 
suitable donor was found. 
DISCUSSION 
The episodes of rejection under FK 506 were less frequent 
than in our past experience. 10 the intensity of the rejection 
was milder. and nearly two-thirds ES~F of these were 
reversed easily with a single dose of IV hydrocortisone or 
methylprednisone. 
As time passed during the trial. side effects were delin-
eated. Also. it was shown how effectively FK 506 could be 
used with other agents. A modified shon course of 5-10 mg 
of OKT3 was given for 3 to 5 days and this was effective 
but associated with infectious morbidity. I ~ In six cases. 
OKT3 was used to control moderate rejection as the first 
choice of antirejection treatment. and in eight more pa-
tients it was used in conjunction with steroid bolus ther-
apy. In this series. there were only two transplants lost 
directly to uncontrollable rejection. OKT3 treatment was 
not used in either case. OKD might be considered a 
course of last appeal. but a dangerous one. 
We evaluated the policy of high dose steroid prophylaxis 
in the first week for the first half of our patients vs 
limitation of steroids for the second half. There was an 
increase in the incidence of rejecllon from 31 % to 48% and 
the first episode of rejection appeared to be earlier in the 
low steroid cohort. However. (his v.as not statistically 
significant (chi·square t test). Since the rejection episodes 
are so readily reversible. the appeal of high dose prophy-
lactic steroids is limited in any case. 
SUMMARY AND CONCLUSIONS 
FK S06 therapy with low doses of steroids was adequate to 
control rejection in most liver recipients. Rejection epi-
sodes were readily reversed ~ith single IV doses of 
methylprednisone or hydroconisone. Short courses of 
OKT) (3 to 5 days 5-10 mL) controlled severe rejections. 
The rate of retransplantation directly due to rejection was 
low (1.6%). There was a limited need for steroids either 
early or out to 6 to 12 months. 
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